Detailansicht

Wissensnetz

Person

Jens Siveke (1973-)

Name	Jens Siveke
Zeit	1973- (Lebensdaten)
Ort	Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr. med.
Variante	Jens Thomas Siveke Jens T. Siveke
Beziehung	Universitätsklinikum Essen Deutsches Krebsforschungszentrum
Weitere Angaben	Am Deutschen Konsortium für Translationale Krebsforschung (DKTK)", Standort Universitätsklinikum Essen tätig
Datensatztyp	Person
GND-Nummer	123603498
Datensatz-ID	123603498
Beteiligt an alle anzeigen P-move: a randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapy Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment Characterization and targeting of ribosome biogenesis in cellular and tissue subtypes of pancreatic ductal adenocarcinoma Exploiting genetic vulnerabilities for BAP1 loss by synthetic lethality Molekulare Charakterisierung von Cholangiokarzinomen mit Fokus auf DNA Schadensreparaturgene in einem onkologischen Spitzenzentrum Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO) Evaluation of a liquid biopsy approach in pancreatic ductal adenocarcinoma MCL1 as putative target in pancreatoblastoma Das Pankreaskarzinom : Klinische Projekte der onkologischen Studiengruppen in Deutschland (ACO, AIO und ARO) Epigenetic and phenotypic plasticity as mediators of resistance to oncogenic pathway targeting Exploring Tumor-Associated Macrophage Heterogeneity and Their Responses to MEK Inhibition in Pancreatic Ductal Adenocarcinoma TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma Localized angiosarcoma, not one disease: a retrospective single-center study on prognosis depending on the primary site and etiology Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus : a randomized, placebo-controlled phase II AIO trial with serum biomarker program T-Helferzellen vom Th1-, Th2-Typ : chemokin-induzierte Chemotaxis und Chemokinrezeptor-Expression T-Helferzellen vom Th1-Th2-Typ : chemokin-induzierte Chemotaxis und Chemokinrezeptor-Expression

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Jens Siveke (1973-)

P-move: a randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapy

Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment

Characterization and targeting of ribosome biogenesis in cellular and tissue subtypes of pancreatic ductal adenocarcinoma

Exploiting genetic vulnerabilities for BAP1 loss by synthetic lethality

Molekulare Charakterisierung von Cholangiokarzinomen mit Fokus auf DNA Schadensreparaturgene in einem onkologischen Spitzenzentrum

Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer

Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols

A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO)

Evaluation of a liquid biopsy approach in pancreatic ductal adenocarcinoma

MCL1 as putative target in pancreatoblastoma

Das Pankreaskarzinom : Klinische Projekte der onkologischen Studiengruppen in Deutschland (ACO, AIO und ARO)

Epigenetic and phenotypic plasticity as mediators of resistance to oncogenic pathway targeting

Exploring Tumor-Associated Macrophage Heterogeneity and Their Responses to MEK Inhibition in Pancreatic Ductal Adenocarcinoma

TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer

Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma

[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma

Localized angiosarcoma, not one disease: a retrospective single-center study on prognosis depending on the primary site and etiology

Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma

Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus : a randomized, placebo-controlled phase II AIO trial with serum biomarker program

T-Helferzellen vom Th1-, Th2-Typ : chemokin-induzierte Chemotaxis und Chemokinrezeptor-Expression

T-Helferzellen vom Th1-Th2-Typ : chemokin-induzierte Chemotaxis und Chemokinrezeptor-Expression